 |
|
Mesothelioma: A Killer
Lurks in the Lungs |
|
 |
Many With Non-Hodgkins Lymphoma Under-treated |
|
September 23, 2004 08:48:47 PM PDT , HealthDay |
|
THURSDAY, Sept. 23 (HealthDayNews) -- About half the patients with aggressive non-Hodgkin's lymphoma in the United States don't receive the recommended dose and schedule of chemotherapy, which reduces their chances for remission or cure, says a University of Rochester Medical Center study.
Researchers reviewed data for 4,552 patients in 567 cancer practices across the United States and found that between 48 percent to 53 percent of patients with non-Hodgkin's lymphoma (NHL) were given less than 85 percent of the recommended chemotherapy dose intensity. This was due to treatment delays of at least one week or dose reduction, the researchers said.
Patients over age 60 had twice the risk of being under-treated, the study found.
"The data point to an alarming pattern in the treatment of patients with aggressive and potentially curable NHL: too many patients do not receive the chemotherapy doses that they need in order to have the best chance of complete remission or cure," lead researcher Dr. Gary Lyman, director of health services and outcomes research at the Wilmot Cancer Center at the University of Rochester Medical Center, said in a prepared statement.
The study cited both planned and unplanned reductions in treatment as the reasons for under-treatment of NHL patients. Unplanned reductions were due to treatment complications such as side effects caused by chemotherapy.
The study appears in the Sept. 20 online issue of the Journal of Clinical Oncology.
More information
The American Cancer Society has more about non-Hodgkin's lymphoma. |
Hormone effects unlikely with asthma drug
Last Updated: 2004-09-23 16:04:06 -0400 (Reuters Health)
NEW YORK (Reuters Health) - The inhaled drug fluticasone propionate is unlike to cause major hormone disturbances in patients with severe asthma, according to a report in the Annals of Allergy Asthma and Immunology.
Previous reports have yielded conflicting results regarding whether fluticasone, an inhaled steroid drug, can disrupt steroid hormones in the body.
In the current study, 10 patients with severe asthma and 10 healthy comparison subjects were treated with fluticasone for 2 weeks. During that time, levels of an important steroid hormone called cortisol were measured.
According to Dr. Daniel K. C. Lee and colleagues, from Ninewells Hospital in Dundee, Scotland, fluticasone had no major effect on cortisol levels. In contrast, in healthy subjects, use of the drug did reduce hormone production.
"It is reassuring to know that patients with severe asthma" do not experience hormone disturbances when using fluticasone, the investigators write.
Nonetheless, they say, "vigilance is required because there may be susceptible patients who might be particularly sensitive" to fluticasone and similar drugs.
SOURCE: Annals of Allergy, Asthma, and Immunology, September 2004.
Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Continue with:
|
